Kalaris Reports Second Quarter 2025 Financial Results And Provides Business Updates
Aug 13 (Reuters) - Kalaris Therapeutics Inc KLRS.O:
KALARIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
KALARIS THERAPEUTICS INC - CASH & CASH EQUIVALENTS OF $88.4M AS OF JUNE 30, 2025, EXPECTED TO FUND OPERATIONS INTO Q4 2026
KALARIS THERAPEUTICS INC - NET LOSS $11.4M OR $0.61/SHARE IN Q2 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SpaceX IPO Guide: Can You Buy SpaceX IPO Shares on Robinhood? How Can Investors in Asia and Europe Buy SpaceX IPO Shares?

Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

Chevron Stock Analysis: A Stock Warren Buffett Bet Big On—Should You Invest in 2026 Despite High Oil Prices?

IonQ vs. Rigetti Computing: Which Quantum Computing Stock Has the Edge Now?

Tradingkey








